- Home
- Software
- usa new york
- clinically studied
Show results for
Refine by
Clinically Studied Software In Usa New York
5 software items found
by:Medidata based inNew York, NEW YORK (USA)
Patient Cloud is a suite of powerful solutions that makes it simple and engaging for patients to participate in any clinical trial – so your trials are easier, faster, and produce better results. Built into the Medidata Clinical Cloud platform, Patient Cloud solutions combine Medidata’s leading clinical trial technology with unmatched patient centricity by design. Only Patient Cloud ...
by:Medidata based inNew York, NEW YORK (USA)
Medidata’s Rave EDC (Electronic Data Capture) is the most advanced, robust, and secure EDC system for clinical trial site, patient, and lab data capture and management. Rave EDC is the cornerstone of the Medidata Clinical Cloud® – the unified clinical research platform that connects processes, eliminates data reconciliation, and ...
by:Medidata based inNew York, NEW YORK (USA)
Medidata is the only provider capable of taking 20+ years of data and insights and operationalizing it across the trial continuum, moving you beyond static, siloed systems, to an ecosystem providing a complete view of the patient and site experience, and unified workflows driving faster trial timelines. Medidata powers study teams with technology that spans the trial lifecycle ...
Manufactured by:Agilent Technologies, Inc. based inSanta Clara, CALIFORNIA (USA)
Agilent SureCall software allows clinical researchers who use NGS panels for inherited diseases and cancer, to analyze, visualize, and contextualize NGS data using a single application. SureCall is a key component of Agilent's NGS Target Enrichment solution which includes SureDesign, Agilent's custom design tool and HaloPlex or SureSelect Target Enrichment panels. Download SureCall free-of-charge ...
Manufactured by:Agilent Technologies, Inc. based inSanta Clara, CALIFORNIA (USA)
The SureSelect Focused Exome is a highly targeted design that enables analysis of only the disease-associated targets providing deep coverage even on a benchtop sequencer. This design provides 20 or more reads for 95% of targets at 1.5Gb (100x) of sequencing and 98% of targets with 3Gb (200x) of sequencing enabling superior coverage of disease-associated regions even when sequenced on benchtop ...